In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2334-2338

  Citron, D M ^a,b   Merriam, C V ^a   Tyrrell, K L ^a   Warren, Y A ^a   Fernandez, H ^a   Goldstein, E J C ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b R M Alden Research Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACITRACIN; CEFOXITIN; CLINDAMYCIN; LINEZOLID; METRONIDAZOLE; RAMOPLANIN; TEICOPLANIN; VANCOMYCIN;

ACTINOMYCES; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; DILUTION; DRUG ACTIVITY; EUBACTERIUM; FECES MICROFLORA; FUSOBACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM; VEILLONELLA;

ACETAMIDES; ACTINOMYCES; ANTI-BACTERIAL AGENTS; BACITRACIN; BACTERIA, ANAEROBIC; CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; EUBACTERIUM; FECES; INTESTINES; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PEPTIDES, CYCLIC; PEPTOSTREPTOCOCCUS; PROPIONIBACTERIUM; TEICOPLANIN; VANCOMYCIN;

EID: 0038311977     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2334-2338.2003     Document Type: Article

References (19)

1. Barry, A. L., M. A. Pfaller, and P. C. Fuchs. 1993. Ramoplanin susceptibility testing criteria. J. Clin. Microbiol. 31:1932-1935.
2. Bertazzoni Minelli, E., A. Benini, L. Vicentini, and A. Muner. 1995. Antibiotics and their interaction with intestinal contents. Microecol. Ther. 25:360-367.
3. Biavasco, F., E. Manso, and P. E. Varaldo. 1991. In vitro activities of ramoplanin and four glycopeptides antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 35:195-197.
4. Carmeli, Y., G. M. Eliopoulos, and M. H. Samore. 2002. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg. Infect. Dis. 8:802-807.
5. Collins, L. A., G. M. Eliopoulos, C. B. Wennersten, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37:1364-1366.
6. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
7. Edlund, C., L. Barkholt, B. Olsson-Liljequist, and C. E. Nord. 1997. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin. Infect. Dis. 25:729-732.
8. Hacek, D. M., P. Bednarz, G. A. Noskin, T. Zembower, and L. R. Peterson. 2001. Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program. J. Clin. Microbiol. 39:1152-1154.
9. Jones, R, N., and A. L. Barry. 1989. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn. Microbiol. Infect. Dis. 3:279-282.
10. Lawrence, T., C. Rotstein, T. Beam, E. A. Gorzynski, D. Amsterdam. 1993. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicrob. Agents Chemother. 37:896-900.
11. Manzor, O., J. Pawlak, and L. Saravolatz. 1999. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:31-36.
12. Mobaraki, N., J. M. Quale, and D. Landman. 1994. Bactericidal activity of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.
13. NCCLS. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 5th ed. M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. O'Hare, M. D., G. Ghosh, D. Felmingham, and R. N. Gruneberg. 1990. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial. J. Antimicrob. Chemother. 25:217-220.
15. Poduval, R. D., R. P. Kamath, M. Corpuz, E. P. Norkus, and C. S. Pitchumoni. 2000. Clostridium difficile and vancomycin-resistant Enterococcus: the new nosocomial alliance. Am. J. Gastroenterol. 95:3513-3515.
16. Rolston, K. V. I., N. Dholakia, D. H. Ho, B. Leblanc, T. Dvorak, and H. Streeter. 1996. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against Gram-positive clinical isolates from cancer patients. J. Antimicrob. Chemother. 38:265-269.
17. Somner, E. A., and P. E. Reynolds. 1990. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34:413-419.
18. Vollard, E. J., and H. A. Clasener. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414.
19. Wong, M. T., C. A. Kaufman, H. C. Stanford, P. Linden, G. Fort, H. J. Fuchs, S. B. Porter, R. P. Wenzel, and the Ramoplanin VRE2 Clinical Study Group. 2001. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin. Infect. Dis. 33:1476-1482.